Qiagen Collaborates with Institut Curie to Develop High-Throughput RNAi Tools
News Oct 13, 2005
Qiagen and Institut Curie have announced a collaboration to develop tools for high-throughput RNAi screening as part of the Institut Curie BioPhenics project.
This project, led by Drs Jacques Camonis and Franck Perez, aims to use RNAi technology in conjunction with advanced systematic phenotypic analysis to accelerate cancer drug discovery.
“As one of the largest cancer research centers in Europe, part of the ongoing research at Institut Curie is dedicated to the understanding of how cells become cancerous,” said Jacques Camonis, head of the BioPhenics project in the Translational Department at Institut Curie.
“The goal of the 'BioPhenics' project is to apply cell biology and microscopic imaging to cancer research for a deeper understanding, improved target validation and, ultimately, more efficient cancer drug discovery.”
“Qiagen is pleased to be able to contribute to this ambitious and exciting research,” said Jie Kang, V.P. of R & D at Qiagen.
“The combination of Qiagen advanced siRNA design and extremely efficient HiPerFect delivery reagent should contribute greatly to the overall goals of the project.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019